Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis

Bone

Volumn 46, Issue 6, 2010, Pages 1613-1619

  Canon, Jude ^a   Bryant, Rebecca ^a   Roudier, Martine ^b   Osgood, Tao ^a   Jones, Jon ^b   Miller, Robert ^b   Coxon, Angela ^a   Radinsky, Robert ^a   Dougall, William C ^b  

^a AMGEN INC   (United States)

^b AMGEN INC   (United States)

Author keywords

Bone metastasis; Osteolysis; Osteoprotegerin; Panitumumab; RANK ligand

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PANITUMUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BONE MATRIX; BONE METASTASIS; CELL CYCLE ARREST; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MICE; MICE, NUDE; NEOPLASM METASTASIS; OSTEOPROTEGERIN; RANDOM ALLOCATION; RANK LIGAND; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77953026275     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.03.001     Document Type: Article

References (28)

1. Coleman R.E. Skeletal complications of malignancy. Cancer 1997, 80:1588-1594.
2. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
3. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
4. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268.
5. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
6. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 2004, 1655-1664.
7. Morony S., Capparelli C., Sarosi I., Lacey D.L., Dunstan C.R., Kostenuik P.J. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001, 61:4432-4436.
8. Miller R., Jones J., Tometsko M., Armstrong A., Zhang N., Leal J., et al. Antitumor efficacy of the RANK ligand inhibitor OPG-Fc in the MDA-231 breast cancer and PC3 prostate cancer experimental osteolytic metastases models. J Bone Miner Res 2005, 20:S117.
9. Morony S., Sarosi I., Doerr N., Capparelli C., Warmington K., Cheng Y., et al. OPG prevents bone destruction and decreases skeletal tumor burden in an experimental model of tumor metastasis to bone. J Bone Miner Res 2000, 15:S209.
10. Zheng Y., Zhou H., Brennan K., Blair J.M., Modzelewski J.R.K., Seibel M.J., et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 2007, 40:471-478.
11. Canon J.R., Roudier M., Bryant R., Morony S., Stolina M., Kostenuik P.J., et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 2008, 25:119-129.
12. Zheng Y., Zhou H., Modzelewski J.R., Kalak R., Blair J.M., Seibel M.J., et al. Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone. Cancer Res 2007, 67:9542-9548.
13. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008, 358:1160-1174.
14. Normanno N., De Luca A., Aldinucci D., Maiello M.R., Mancino M., D'Antonio A., et al. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer 2005, 12:471-482.
15. Zhu J., Jia X., Xiao G., Kang Y., Partridge N.C., Qin L. EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. J Biol Chem 2007, 282:26656-26664.
16. Foon K.A., Yang X.D., Weiner L.M., Belldegrun A.S., Figlin R.A., Crawford J., et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004, 58:984-990.
17. Lynch D.H., Yang X.D. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 2002, 29:47-50.
18. Yang X.D., Jia X.C., Corvalan J.R., Wang P., Davis C.G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001, 38:17-23.
19. McDorman K., Freeman D., Bush T., Cerretti D., Fanslow W., Starnes C., et al. ABX-EGF tumor penetration and EGFR saturation correlate with pharmacokinetic, pharmacodynamic and anti-tumor activity in an A431 xenograft model system. AACR 95th Annual Meeting Proceedings-supplement 2004, Vol. 45. Abstract LB-240.
20. Dull T., Zufferey R., Kelly M., Mandel R.J., Nguyen M., Trono D., et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998, 72:8463-8471.
21. Feeley B.T., Liu N.Q., Conduah A.H., Krenek L., Roth K., Dougall W.C., et al. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J Bone Miner Res 2006, 21:1571-1580.
22. Miller R.E., Roudier M., Jones J., Armstrong A., Canon J., Dougall W.C. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther 2008, 7:2160-2169.
23. Zhang J., Dai J., Qi Y., Lin D.L., Smith P., Strayhorn C., et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001, 107:1235-1244.
24. Ignatoski K.M., Escara-Wilke J.F., Dai J.L., Lui A., Dougall W., Daignault S., et al. RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model. Prostate 2008, 68:820-829.
25. Guise T.A., Mundy G.R. Cancer and bone. Endocr Rev 1998, 19:18-54.
26. Nemeth J.A., Yousif R., Herzog M., Che M., Upadhyay J., Shekarriz B., et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002, 94:17-25.
27. Hirata A., Ogawa S., Kometani T., Kuwano T., Naito S., Kuwano M., et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002, 62:2554-2560.
28. Bruns C.J., Harbison M.T., Davis D.W., Portera C.A., Tsan R., McConkey D.J., et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000, 6:1936-1948.